Search results for "models"

showing 10 items of 8211 documents

Bacteria-specific cytotoxic CD8+ T cells: a missing link in the pathogenesis of the HLA-B27-associated spondylarthropathies.

1994

The term seronegative spondylarthropathies is used for an entity of rheumatic syndromes of peripheral joints and the spine (ankylosing spondylitis, reactive arthritis, Reiter's syndrome, arthritis in psoriasis and in inflammatory bowel disease) which are strongly associated with the MHC class I molecule HLA-B27. However, the mechanisms whereby HLA-B27 confers disease susceptibility have so far remained unknown. There is strong evidence that gut inflammation and infection with gram-negative bacteria play a role in the induction of B27-associated disease. HLA-B27, like other MHC class I molecules, physiologically binds antigenic peptides in its binding groove and presents them to CD8+ T lymph…

musculoskeletal diseasesCytotoxicity ImmunologicAnkylosisEpitopeEpitopesAntigenEnterobacteriaceaeMHC class IMedicineCytotoxic T cellAnimalsHumansSpondylarthropathiesHLA-B27 AntigenHLA-B27Antigens Bacterialbiologybusiness.industryArthritisSynovial MembraneGeneral MedicineDisease Models AnimalImmunologybiology.proteinBacterial antigenbusinessCD8Protein BindingT-Lymphocytes CytotoxicAnnals of medicine
researchProduct

Deficiency of Nrf2 accelerates the effector phase of arthritis and aggravates joint disease

2011

14 páginas, 8 figuras, 1 tabla.-- et al.

musculoskeletal diseasesGenetically modified mouseMedicinaNF-E2-Related Factor 2PhysiologyChemokine CXCL1Clinical BiochemistryNitric Oxide Synthase Type IIArthritisMice Transgenicmedicine.disease_causeenvironment and public healthBiochemistryNrf2MicemedicineAnimalsMolecular BiologyGeneral Environmental SciencebiologyInterleukin-6Effectorbusiness.industryArthritisInflammation and degenerationCell Biologyrespiratory systemmedicine.diseaseArthritis ExperimentalInfection and autoimmunity Auto-immunity transplantation and immunotherapy [NCMLS 1]Disease Models AnimalOxidative StressEicosanoidCyclooxygenase 2Rheumatoid arthritisTumor Necrosis FactorsImmunologyOsteocalcinbiology.proteinGeneral Earth and Planetary SciencesJointsTumor necrosis factor alphaImmune Regulation Auto-immunity transplantation and immunotherapy [NCMLS 2]businessOxidation-ReductionHeme Oxygenase-1Oxidative stress
researchProduct

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

2010

Chondrosarcomas are resistant to conventional chemo- and radiotherapy. A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis. We therefore investigated the effect of selective COX-2 inhibition on chondrosarcoma growth. COX-2 expression was studied in central- and peripheral cartilaginous tumours. The effect of COX-2 inhibition was assessed in four high-grade chondrosarcoma cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin E-2 (PGE(2)) ELISA) and cell viability were measured. The (prophylactic) effect of celecoxib o…

musculoskeletal diseasesMaleCancer ResearchPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentChondrosarcomaDrug Evaluation PreclinicalMice NudeAntineoplastic AgentsBone NeoplasmsMiceIn vivomedicineTumor Cells CulturedAnimalsHumansViability assaySulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryCartilagemedicine.diseaseXenograft Model Antitumor AssaysRadiation therapyDisease Models Animalmedicine.anatomical_structureOncologyBone tumours Chondrosarcoma COX-2 inhibition Therapy Xenograft familial adenomatous polyposis cell-line cyclooxygenase-2 inhibitor trial tumors establishment emphasis origin boneCell cultureCelecoxibCyclooxygenase 2CelecoxibPyrazolesChondrosarcomabusinessmedicine.drugProstaglandin E
researchProduct

Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery

2010

Background: According to some current guidelines, extended thromboprophylaxis after hip and knee arthroplasties is recommended. Outpatient prophylaxis with low molecular weight heparins (LMWH) is an important part of this prophylaxis, although the rates of adherence to these regimens is not known. Questions/purposes: We determined (1) the degree of nonadherence (NA) of patients with LMWH outpatient prophylaxis, and (2) whether specific independent factors explain NA. Methods: NA was determined by syringe count and by indirect and direct questions to patients. We defined six different NA indicators. To identify factors explaining LMWH NA, we used three different logistic regression models. R…

musculoskeletal diseasesMaleQuestionnairesmedicine.medical_specialtyHealth Knowledge Attitudes PracticeTime Factorsmedicine.drug_classmedicine.medical_treatmentArthroplasty Replacement HipLow molecular weight heparinRisk AssessmentInjectionsMedication AdherenceAmbulatory careFibrinolytic AgentsClinical ResearchRisk FactorsInternal medicineSurveys and QuestionnairesGermanyAmbulatory CareMedicineHumansOrthopedics and Sports Medicine/dk/atira/pure/core/keywords/559092180Arthroplasty Replacement KneeAgedbusiness.industryAnticoagulantHealth sciencesThrombosisGeneral MedicineHeparinHeparin Low-Molecular-Weightmedicine.diseaseThrombosisArthroplastySurgeryTelephoneLogistic ModelsTreatment OutcomeOrthopedic surgerySurgeryFemalebusinessFibrinolytic agentmedicine.drug
researchProduct

FGFR2mutation in 46,XY sex reversal with craniosynostosis

2015

Patients with 46,XY gonadal dysgenesis (GD) exhibit genital anomalies, which range from hypospadias to complete male-to-female sex reversal. However, a molecular diagnosis is made in only 30% of cases. Heterozygous mutations in the human FGFR2 gene cause various craniosynostosis syndromes including Crouzon and Pfeiffer, but testicular defects were not reported. Here, we describe a patient whose features we would suggest represent a new FGFR2-related syndrome, craniosynostosis with XY male-to-female sex reversal or CSR. The craniosynostosis patient was chromosomally XY, but presented as a phenotypic female due to complete GD. DNA sequencing identified the FGFR2c heterozygous missense mutatio…

musculoskeletal diseasesMalemedicine.medical_specialtyGonadAdolescentDNA Mutational AnalysisMutation MissenseGonadal dysgenesisBiologymedicine.disease_causeCraniosynostosisXY gonadal dysgenesisCraniosynostosesMiceInternal medicineGeneticsmedicineAnimalsHumansMissense mutationGene Knock-In TechniquesReceptor Fibroblast Growth Factor Type 2Molecular BiologyGenetics (clinical)Gonadal Dysgenesis 46XYGeneticsMutationArticlesSyndromeGeneral MedicineSex reversalmedicine.diseaseMice Mutant StrainsDisease Models AnimalEndocrinologymedicine.anatomical_structurePfeiffer syndromeFemaleHuman Molecular Genetics
researchProduct

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct

IAPs: more than just inhibitors of apoptosis proteins.

2008

Inhibitors of apoptosis proteins (IAPs) are a conserved family of proteins identified in species ranging from virus, yeasts, nematodes, fishes, flies and mammals. The common structural feature is the presence of at least one Baculovirus IAP Repeat (BIR) domain. Hence, IAPs are also known as BIR-containing proteins (BIRCs). Most of them display anti-apoptotic properties when overexpressed. In drosophila, IAPs are sufficient and necessary to promote cell survival through a direct regulation of apoptotic proteases called caspases. In mammals, BIRC4/XIAP, the most studied IAP member can directly inhibit the activity of caspase-3, 7 and 9. However, this activity is not conserved in other IAPs an…

musculoskeletal diseasesProteasesCell signalingvirusesCellular differentiationApoptosisModels BiologicalInhibitor of Apoptosis ProteinsCell MovementCellular stress responseMolecular BiologyCaspaseCell ProliferationbiologyCell DifferentiationCell BiologyCell biologyXIAPbody regionsApoptosisCaspasesbiology.proteinbiological phenomena cell phenomena and immunitySignal transductionDevelopmental BiologySignal TransductionCell cycle (Georgetown, Tex.)
researchProduct

Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model

2012

SummaryMyotonic dystrophy type 1 (DM1) is a genetic disease caused by the pathological expansion of a CTG trinucleotide repeat in the 3' UTR of the DMPK gene. In the DMPK transcripts, the CUG expansions sequester RNA-binding proteins into nuclear foci, including transcription factors and alternative splicing regulators such as MBNL1. MBNL1 sequestration has been associated with key features of DM1. However, the basis behind a number of molecular and histological alterations in DM1 remain unclear. To help identify new pathogenic components of the disease, we carried out a genetic screen using a Drosophila model of DM1 that expresses 480 interrupted CTG repeats, i(CTG)480, and a collection of…

musculoskeletal diseasesSarcomerescongenital hereditary and neonatal diseases and abnormalitiesNeuroscience (miscellaneous)lcsh:MedicineMedicine (miscellaneous)RNA-binding proteinGenes InsectBiologyMyotonic dystrophyGeneral Biochemistry Genetics and Molecular BiologyAnimals Genetically Modifiedchemistry.chemical_compoundImmunology and Microbiology (miscellaneous)RNA interferencelcsh:PathologymedicineMBNL1AnimalsDrosophila ProteinsHumansMyotonic DystrophyGeneticsMuscleslcsh:RAlternative splicingNuclear ProteinsRNA-Binding ProteinsEpistasis Geneticmedicine.diseaseDisease Models AnimalchemistryGene Knockdown TechniquesDrosophilaFemaleRNA InterferenceTrinucleotide repeat expansionTrinucleotide Repeat ExpansionDrosophila Proteinlcsh:RB1-214Genetic screenResearch ArticleDisease Models & Mechanisms
researchProduct

Influence of sutures configuration on the strength of tendon-patch joints for rotator cuff tears treatment

2019

Abstract Purpose Massive rotator cuff tears are common in the aging population. The incidence of failed rotator cuff repairs is still quite high, especially in the treatment of full-thickness tears or revision repairs. In this context, natural and synthetic meshes can be used as augmentation scaffolds or as devices to close the gap between a retracted tendon and the bone. The purpose of this work is to evaluate the ultimate tensile strength of different tendon-patch joints in order to consider their use in the treatment of massive cuff tears. Materials and methods Porcine tendons and a synthetic low-density polypropylene mesh have been used. A preliminary study on the tensile strength of te…

musculoskeletal diseasesSwineRotator cuff tearBiocompatible MaterialsContext (language use)Synthetic patchRotator Cuff InjuriesTensile strengthTendonsRotator Cuff03 medical and health sciences0302 clinical medicineExperimental testUltimate tensile strengthAnimalsMedicineRotator cuffRange of Motion ArticularSettore ING-IND/15 - Disegno E Metodi Dell'Ingegneria IndustrialeReverse engineeringJoint (geology)General Environmental ScienceTensile testing030222 orthopedicsSuturesExperimental test; Reverse engineering; Rotator cuff tear; Synthetic patch; Tensile strengthbusiness.industrySuture Techniques030208 emergency & critical care medicinePlastic Surgery Proceduresmusculoskeletal systemTendonmedicine.anatomical_structureModels AnimalCuffGeneral Earth and Planetary SciencesbusinessRange of motionBiomedical engineeringInjury
researchProduct

An update on the relationships between rheumatoid arthritis and atherosclerosis

2010

Rheumatoid arthritis is a chronic inflammatory disease. Cardiovascular events are the most important cause of mortality and morbidity in patients with rheumatoid arthritis. Beyond the traditional cardiovascular risk factors, chronic systemic inflammation has been shown to be a crucial factor in atherosclerosis development and progression from endothelial dysfunction to plaque rupture and thrombosis. Many studies have shown that atherosclerosis is not a passive event like accumulation of lipids in the vessel walls; by contrast, it represents an active inflammation of the vessels. Inflammatory cells such as macrophages, monocytes and T cells play important roles in the development of both rhe…

musculoskeletal diseasesT-LymphocytesAtherosclerosis Rheumatoid arthritis Inflammation Cardiovascular risk10265 Clinic for Endocrinology and DiabetologyInflammation610 Medicine & healthComorbiditySystemic inflammationModels BiologicalMonocytes2705 Cardiology and Cardiovascular MedicineArthritis RheumatoidRisk FactorsImmunopathologymedicineHumansEndothelial dysfunctionAutoimmune diseaseInflammationbusiness.industryVascular diseaseMacrophagesmedicine.diseaseAtherosclerosisThrombosisOxidative StressCardiovascular DiseasesRheumatoid arthritisImmunologyDisease Progressionmedicine.symptomInsulin ResistanceCardiology and Cardiovascular Medicinebusiness
researchProduct